<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916054</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2021-10</org_study_id>
    <nct_id>NCT04916054</nct_id>
  </id_info>
  <brief_title>Time to Surgery and Survival Outcomes for Patients With Resected Colorectal Carcinoma: Multicenter Study (BIG RENAPE)</brief_title>
  <acronym>DELARC</acronym>
  <official_title>Time to Surgery and Survival Outcomes for Patients With Resected Colorectal Carcinoma: Multicenter Study (BIG RENAPE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer (CRC) is diagnosed in one million patients each year worldwide and is the&#xD;
      2nd leading cause of cancer death. Peritoneal metastasis (MP) is seen in 10% of CRC patients&#xD;
      and is the metastatic site with the worst prognosis.&#xD;
&#xD;
      Complete cytoreduction surgery (CCS) is the only treatment that allows for prolonged&#xD;
      survivals. Five-year overall survival (OS) after CCS ranges from 30% to 60% compared with 0&#xD;
      to 5% with exclusive medical treatment.&#xD;
&#xD;
      Chemotherapy (CT) with fluoropyrimidine and oxaliplatin and/or irinotecan 3 months&#xD;
      pre-operatively and 3 months adjuvant is widely used. The benefits of perioperative CT have&#xD;
      been demonstrated in another resectable metastatic site, the liver and has become by&#xD;
      extension a therapeutic standard in France for CRC MPs. However, the impact of delay in the&#xD;
      initiation of surgery and adjuvant or neoadjuvant CT is unknown for CRC MPs.&#xD;
&#xD;
      Several deleterious oncologic effects are related to a long period without treatment between&#xD;
&#xD;
        -  Neoadjuvant chemotherapy and surgery:&#xD;
&#xD;
        -  Surgery and adjuvant chemotherapy.&#xD;
&#xD;
      Several meta-analyses have demonstrated, for at least 13 different cancers, a continuous&#xD;
      association between delays in treatment (CT, radiotherapy, or surgery) and cancer mortality.&#xD;
      For CRC, Hanna's meta-analysis showed that for every 4-week delay in adjuvant surgery or CT,&#xD;
      the risk of cancer death increased by 6 and 13%, respectively.&#xD;
&#xD;
      These long delays between CT and excisional surgery also decrease survival in patients with&#xD;
      liver metastases from colorectal origins and MPs from ovarian origins but this has never been&#xD;
      evaluated in patients with MPs from colorectal origins.&#xD;
&#xD;
      Demonstrating an oncologic impact of therapeutic delays would have several strategic&#xD;
      practical impacts such as:&#xD;
&#xD;
        -  Promoting pre- and post-operative rehabilitation programs to facilitate recovery and&#xD;
           reduce time to retreatment.&#xD;
&#xD;
        -  To use more easily techniques (protective stoma, multi-stage surgery) limiting the risk&#xD;
           of complications and therefore the delays in treatment.&#xD;
&#xD;
        -  Propose clinical research protocols aimed at reducing these delays with knowledge of&#xD;
           plausible statistical hypotheses.&#xD;
&#xD;
      A therapeutic strategy of shortening the time between each treatment therefore deserves to be&#xD;
      evaluated in metastatic forms of colorectal cancer.&#xD;
&#xD;
      The investigators would like to evaluate the hypothesis that shortened time between&#xD;
      treatments could have a prognostic impact on recurrence-free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study including exhaustively all patients operated CC0-CC1 of&#xD;
      peritoneal carcinosis between 2007 and 2019 meeting the inclusion criteria:&#xD;
&#xD;
        -  Patients from the Institut de cancérologie de l'Ouest and the CHU of Lyon for the study&#xD;
           period 2007-2016&#xD;
&#xD;
        -  Patients included in the BIG-RENAPE network between 2016 and 2019&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to determine whether the time between each anti-tumor therapy has a prognostic impact on recurrence-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>recurrence-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact on overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a surgery for peritoneal carcinosis of colorectal origin between 2007 and 2019&#xD;
&#xD;
          -  Patients from the Institut de cancérologie de l'Ouest and the CHU of Lyon for the&#xD;
             study period 2007-2016&#xD;
&#xD;
          -  Patients included in the BIG-RENAPE network between 2016 and 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. Histological evidence of peritoneal metastases&#xD;
&#xD;
          3. Primary colorectal cancer&#xD;
&#xD;
          4. Surgical cytoreduction CC0 or CC1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who has not received at least 3 courses of pre and/or post cytoreduction&#xD;
             chemotherapy&#xD;
&#xD;
          2. Primitive appendicitis&#xD;
&#xD;
          3. Unknown primitive&#xD;
&#xD;
          4. Patient with incomplete CC2 and/or palliative surgery&#xD;
&#xD;
          5. Patient opposed to the use of their data for research.&#xD;
&#xD;
          6. Isolated local pelvic recurrence.&#xD;
&#xD;
          7. Extraperitoneal metastases not resected or destroyed before or during cytoreduction.&#xD;
&#xD;
          8. Patient opposed to the use of his/her data for research purposes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Frédéric DUMONT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frédéric DUMONT, MD</last_name>
    <phone>+33240679900</phone>
    <email>frederic.dumont@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laetitia HIMPE</last_name>
    <email>promotionrc@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU LYON</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier GLEHEN</last_name>
      <email>olivier.glehen@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Laurent VILLENEUVE</last_name>
      <email>laurent.villeneuve@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric DUMONT, MD</last_name>
      <email>frederic.dumont@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

